# Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

> **NCT00296374** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 353 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00296374
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2011-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00296374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00296374, "Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00296374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*